Sign up to save your podcasts
Or
Share Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ticiana Leal, MD / Neal Ready, MD, PhD - From Cases to Care: Personalizing First-Line Immunotherapy in Advanced NSCLC Through a Patient-Centered Approach
Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.
View all episodes
By Answers in CME
4.8
66 ratings
Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.
More shows like CME in Minutes: Education in Primary Care
View all
The Curbsiders Internal Medicine Podcast
3,332 Listeners
Core IM | Internal Medicine Podcast
1,140 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Oncology & Hematology
6 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
5 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners